ReleaseWire Connect

Antiviral drugs are used for the treatment of infection caused due to hepatitis C. These drugs inhibit the growth of protease or polymerase enzyme of the virus. However, there is no vaccine for the prevention infections caused due to hepatitis C virus, which offers lucrative growth opportunities for market players. Increasing number of people suffering from chronic hepatitis C is expected to boost growth of the global hepatitis C drug market. For instance, according to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide.

Companion Diagnostics Market Size, Share, Trends, and Forecast 2018 - 2026

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is an infection of the skin and soft tissue that impacts the epidermis, dermis, and subcutaneous tissues. According to the U.S. Food and Drug Administration (FDA), ABSSSIs are lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. ABSSSI is caused due to pathogens such as Beta-hemolytic Streptococcus, Methicillin sensitive Staphylococcus aureus (MSSA), Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and Methicillin resistant Staphylococcus aureus (MRSA). High incidence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. has led to several challenges in the treatment of ABSSSI.

Acute lymphoblastic leukemia (ALL) is a cancer of bone marrow and blood that is caused due to uncontrolled generation of lymphoblast, which are immature white blood cells (WBCs). Renal failure, pneumonia, respiratory distress, and bone pain are some of the common symptoms of ALL. The progression rate is high in ALL and the condition may lead to death within few months, if left untreated. Lymphoblast malfunction and accumulate around healthy cells. In ALL, the bone marrow loses the ability to form sufficient numbers of red blood cells (RBCs), white blood cells, and platelets, which may often lead to recurrent infections, anemia, bleeding and bruising. The tumor can spread to other parts of the body including lymph nodes, liver, spleen, and the central nervous system. ALL is highly prevalent in children and requires timely treatment and diagnosis for better outcome.

Increasing population of people aged 60 and above is expected to propel growth of the global sarcopenia treatment market. For instance, according to the World Health Organization, by 2050, the world's population aged 60 years and above is expected reach 2 billion from 900 million in 2015. Major institutes and regulatory bodies are focused on increasing awareness regarding sarcopenia, which is also expected to contribute to market growth. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on symptoms and daily impacts of their condition.

Healthcare EDI Market Size, Share, Outlook and Opportunity Analysis 2018 - 2026

The boost growth of theglobal drug discovery marketinclude, high prevalence of several diseases, emergence of new diseases, increasing development in biotechnology and pharmaceuticals sectors, and R&D of new active ingredients for use in drug development. Increasing number of current drugs are expected to lose patents, which offers lucrative growth opportunities for market players. For instance, in 2017, manufacturers such as Eli Lilly, Bristol-Myers Squibb, Pfizer, Takeda, and Gilead lost patents for some of their major revenue generating therapies used for the treatment of multiple sclerosis, HIV, erectile dysfunction, and cancer. Loss of patents promotes market players to focus on R&D of new therapies. Moreover, patent loss also offers lucrative opportunities for generic manufacturers. Therefore, key players in the market are focused on developing new and effective drugs to remain competitive in the market.

Biopharmaceutical organizations are focused on research and development activities in novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and some rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S.

Drug Discovery Informatics Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Recombinant protein is a protein that is encoded by a gene named 'recombinant DNA' and has been cloned in a system, which supports expression of gene and translation of messenger RNA. Recombinant proteins are classified on the basis of type namely hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others. Manufacturers such as Biocon, Ltd., Eli Lilly, and Company, Genentech, Inc., Novo Nordisk Pharmatech A/S, Prospec-Tany Technogene Ltd., Abcam plc, and BPS Bioscience, Inc. offer recombinant proteins for various applications such as drug discovery and development.